The HTA Core Model®—10 Years of Developing an International Framework to Share Multidimensional Value Assessment

Value in Health

Volumn 20, Issue 2, 2017, Pages 244-250

  Kristensen, Finn Børlum ^a,b   Lampe, Kristian ^c   Wild, Claudia ^d   Cerbo, Marina ^e   Goettsch, Wim ^f,g   Becla, Lidia ^a  

^a Danish Health and Medicines Authority   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e National Agency for Regional Health Services   (Italy)

^f Dutch National Health Care Institute (ZIN)   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

decision making; health care; health technology assessment; methodology

Indexed keywords

ARTICLE; CONCEPTUAL FRAMEWORK; DECISION MAKING; DIAGNOSIS; ECONOMIC EVALUATION; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; MEDICAL TECHNOLOGY; PHARMACEUTICS; PHARMACOECONOMICS; PRIORITY JOURNAL; SCREENING; SURGERY; BIOMEDICAL TECHNOLOGY ASSESSMENT; EUROPE; INFORMATION DISSEMINATION; INTERNATIONAL COOPERATION; PROCEDURES; THEORETICAL MODEL;

DECISION MAKING; EUROPE; INFORMATION DISSEMINATION; INTERNATIONAL COOPERATION; MODELS, THEORETICAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85013675452     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.12.010     Document Type: Article

References (33)

1. [1] European network for Health Technology Assessment. EUnetHTA activities 2006–20. Available from: http://eunethta.eu/activities. [Accessed January 18, 2017].
2. [2] Lampe, K., Mäkelä, M., Garrido, M.V., et al. European network for Health Technology Assessment. The HTA Core Model—a novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care 25:Suppl. 2 (2009), 1–8.
3. [3] Kristensen, F.B., Mäkelä, M., Neikter, S.A., et al. European network for Health Technology Assessment. Planning, development, and implementation of a sustainable European network for health technology assessment. Int J Technol Assess Health Care 25:Suppl. 2 (2009), 84–91.
4. [4] Kristensen, F.B., Lampe, K., Chase, D., et al. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA. Int J Technol Assess Health Care 25:Suppl. 2 (2009), 68–73.
5. [5] European network for Health Technology Assessment. HTA Core Model®. Available from: http://www.eunethta.eu/hta-core-model. [Accessed January 18, 2017].
6. [6] European network for Health Technology Assessment. HTA Core Model handbook. Available from: http://meka.thl.fi/htacore/ViewHandbook.aspx. [Accessed January 18, 2017].
7. [7] European network for Health Technology Assessment. EUnetHTA final technical report years 2006–2008. Available from: http://ec.europa.eu/health/ph_systems/docs/eunethta_report_en.pdf. [Accessed January 18, 2017].
8. [8] European network for Health Technology Assessment. EUnetHTA JA2 stakeholder forum. Available from: http://www.eunethta.eu/eunethta-ja2-stakeholder-forum. [Accessed January 18, 2017].
9. [9] European network for Health Technology Assessment. EUnetHTA joint assessments. Available from: http://www.eunethta.eu/joint-assessments. [Accessed January 18, 2017].
10. [10] European network for Health Technology Assessment. EUnetHTA guidelines. Available from: http://www.eunethta.eu/eunethta-guidelines. [Accessed January 18, 2017].
11. [11] European network for Health Technology Assessment. EUnetHTA planned and ongoing projects (POP) database. Available from: http://www.eunethta.eu/pop-database. [Accessed January 18, 2017].
12. [12] European network for Health Technology Assessment. Submission template for pharmaceuticals and submission template for medical devices. Available from: http://eunethta.eu/outputs/submission-template-pharmaceuticals-and-submission-template-medical-devices. [Accessed January 18, 2017].
13. [13] European network for Health Technology Assessment. EUnetHTA early dialogue consolidated procedure. Available from: http://eunethta.eu/outputs/eunethta-early-dialogue-consolidated-procedure. [Accessed January 18, 2017].
14. [14] European network for Health Technology Assessment. EUnetHTA core protocol pilot for AEG. Available from: http://eunethta.eu/outputs/eunethta-core-protocol-pilot-aeg. [Accessed January 18, 2017].
15. [15] European network for Health Technology Assessment. National uptake. Available from: http://eunethta.eu/national-uptake. [Accessed January 18, 2017].
16. [16] European network for Health Technology Assessment. Procedure manual: rapid relative effectiveness assessment of pharmaceuticals. Available from: http://eunethta.eu/outputs/procedure-manual-strand-rapid-relative-effectiveness-assessment-pharmaceuticals. [Accessed January 18, 2017].
17. [17] EUR-Lex. Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A31989L0105. [Accessed January 18, 2017].
18. [18] Kleijnen, S., Pasternack, I., Casteele Van de, M., et al. Standardised reporting for rapid relative effectiveness assessments of pharmaceuticals. Int J Technol Assess Health Care 30 (2014), 488–496.
19. [19] European network for Health Technology Assessment. The HTA Core Model® guiding principles on use. Available from: http://www.eunethta.eu/outputs/hta-core-model-guiding-principles-use. [Accessed January 18, 2017].
20. [20] European network for Health Technology Assessment. Procedure manual: rapid assessments of other health technologies such as medical devices, surgical interventions or diagnostics. Available from: http://eunethta.eu/outputs/procedure-manual-strand-b-rapid-assessments-other-health-technologies-such-medical-devices-s. [Accessed January 18, 2017].
21. [21] European network for Health Technology Assessment. Roche Pharma review of the HTA Core Model® from a pharmaceutical perspective, full report and appendices. Available from: http://eunethta.eu/news/roche-pharma-reviews-hta-core-model-pharmaceutical-perspective. [Accessed January 18, 2017].
22. [22] European network for Health Technology Assessment. EUnetHTA Joint Action 3 2016–2020. Available from: http://www.eunethta.eu/activities/joint-action-3/jointaction31/eunethta-joint-action-3-2016-2020. [Accessed January 18, 2017].
23. [23] European network for Health Technology Assessment. HTA Core Model® gets an update—open for use by anyone. Available from: http://www.eunethta.eu/news/hta-core-model-gets-update-open-use-anyone. [Accessed January 18, 2017].
24. [24] Huic, M., Nachtnebel, A., Zechmeister, I., et al. Collaboration in HTA through the EUnetHTA Joint Action project (2010–2012): 4 case studies. Int J Technol Assess Health Care 29 (2013), 323–330.
25. [25] Kleijnen, S., Fathallah, M., van der Linden, M.W., et al. Can a joint assessment provide relevant information for national/local relative effectiveness assessments? An in-depth comparison of pazopanib assessments. Value Health 18 (2015), 663–672.
26. [26] Nachtnebel, A., Mayer, J., Erdös, J., et al. HTA goes Europe: Europäische Zusammenarbeit in gemeinsamen Nutzenbewertungen und methodischen Fragen wird real. Z Evid Fortbild Qual Gesundwes 109 (2014), 291–299.
27. [27] Wild, C., Vicari, N., Cerbo, M., Nachtnebel, A., European collaboration in health technology assessment (HTAs) of medical devices. J Med Device Regul 13 (2016), 30–37.
28. [28] Lo Scalzo, A., Vicari, N., Corio, M., et al. Collaborative models for the joint production of core health technology assessments: negative and positive aspects for the joint work of different European agencies. Int J Technol Assess Health Care 30 (2014), 536–543.
29. [29] Krüger, L.J., Evers, S., Hiligsmann, M., Wild, C., Divergent evidence requirements for authorization and reimbursement of high-risk medical devices—the European situation. Health Policy Technol 3 (2014), 253–263.
30. [30] Wild, C., Erdös, J., Zechmeister-Koss, I., Contrasting clinical evidence for market authorization of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessments. BMC Cardiovasc Disord, 14, 2014, 154.
31. [31] Lampe, K., Pasternack, I., Saarekas, O., et al. Developing the HTA core model for the online environment. Int J Technol Assess Health Care 30 (2014), 478–487.
32. [32] Lo Scalzo A, Lenzi L, Chiarolla E, et al. HTA report: new devices for the management of glycaemia in young diabetics. 2012. Available from: http://www.salute.gov.it/imgs/C_17_pagineAree_1202_listaFile_itemName_23_file.pdf. [Accessed January 18, 2017].
33. [33] Sorenson, C., Drummond, M., Improving medical device regulation: The United States and Europe in perspective. Milbank Q 92 (2014), 114–150.